Roche Holdingの空売り状況は、投資家がRoche Holdingの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Roche Holding (OTC:RHHBY) 株価情報, 空売り情報

Roche Holding

ROCHE HLDG LTD SPONS

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

Roche Holding AG

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43023003/outlook-therapeutics-announces-complete-twelve-week-efficacy-and-safety-results-of-norse-eight-cli" rel="noreferrer noopener">degeneration (wet AMD) patients</a>.
ONS-5010 demonstrated non-inferiority to Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) / Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.
The difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity (BCVA) letters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
BCVA measures how well a person can see after wearing corrective lenses, such as glasses or contact lenses.
In the intent-to-treat (ITT) population, NORSE EIGHT demonstrated a mean 5.5 letter improvement in BCVA in the ONS-5010 arm and 6.5 letter improvement in BCVA in the ranibizumab arm.
As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 outlined in the special protocol assessment (SPA) with the U.S. <a target="_blank" href="https://www.benzinga.com/24/11/42214804/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.
However, BCVA data across all study timepoints demonstrated an improvement in vision, increasing over time, and the presence of biologic activity.
Overall, in NORSE EIGHT, ONS-5010 demonstrated mean visual acuity improvements of +3.3 letters at week 4, +4.2 letters at week 8, and +5.5 letters at week 12.
ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab.
ONS-5010/LYTENAVA (bevacizumab gamma) has been approved in the European Union and the United Kingdom. Outlook Therapeutics intends to begin launching in Europe in the first half of calendar 2025.
The company also entered into agreements for warrant inducement transactions expected to result in up to $20.4 million in gross proceeds.
The company will use the proceeds to fund its ONS-5010 clinical development programs, the European commercial launch of LYTENAVA, and working capital and general corporate purposes.
Price Action: OTLK stock is down 9.78% at $2.06 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion" target="_blank" rel="noreferrer noopener">Ingevity Explores Strategic Options For Performance Chemicals Segment To Strengthen Portfolio, Projects FY24 Revenue At $1.40 Billion</a></li>
</ul>

Biotech

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

OTLK

RHHBY

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

<ul>
<li>The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2</li>
<li>The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients.</li>
<li>B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is one of the most common cancers in the US.3</li>
</ul>

RHHBF

RHHVF

Roche's VENTANA ISH Test Secures FDA Clearance For Accurate B-Cell Lymphoma Diagnosis

<ul>
<li>The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images. &nbsp;</li>
<li>This 240-slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab. &nbsp;</li>
<li>Primary diagnosis in digital pathology helps enhance diagnostic accuracy, consistency, and speed by providing high-resolution images and advanced analysis tools.</li>
</ul>

Roche's Digital Pathology Dx System Expands With FDA Approval Of High-Capacity VENTANA DP 600 Scanner

Under the agreement, Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009. The two parties will jointly focus on the early-stage development of this ADC candidate, after which Roche will take over full development. Innovent will receive an upfront payment of US$80 million and is eligible to receive up to US$1 billion in development and commercial milestone payments, along with tiered royalties on net sales.

IVBIY

Reported Wednesday, Roche And Innovent Forge Exclusive Global License Deal To Develop DLL3-Targeting ADC For Advanced Lung Cancer

On Monday, Sangamo Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Pfizer decided to terminate the global collaboration and license agreement <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42733065/sangamo-therapeutics-to-regain-full-rights-to-hemophilia-a-gene-therapy-program-following-pfizers-" rel="noreferrer noopener">between the parties</a>. Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug With Six Months</a>
In July 2024, Pfizer announced topline results from the Phase 3 AFFINE trial of giroctocogene fitelparvovec, which demonstrated that the trial met the primary and key secondary objectives of superiority <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39937203/sangamo-stock-spikes-as-pfizer-partnership-meets-goal-in-late-stage-study" rel="noreferrer noopener">compared to prophylaxis</a>.
&#8220;&#8230;we believe it is well positioned for regulatory submissions and potential commercialization,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. &#8220;While we were surprised and extremely disappointed by Pfizer&#8217;s decision to end our collaboration so close to the anticipated BLA and MAA submissions&#8230;&#8221;
The collaboration and license agreement with Pfizer will terminate effective April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.
Sangamo believes that its recently announced partnerships with Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech and Astellas Pharma Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its neurology genomic medicine pipeline.
The company prepares to initiate the expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and file an anticipated Clinical Trial Authorisation submission for the prion disease program in Q4 2025, each subject to securing additional funding.
Price Action: SGMO stock is down 54.70% at $1.106 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42727774/precigen-shares-surges-over-25-after-bla-submission-for-first-ever-rrp-gene-therapy" target="_blank" rel="noreferrer noopener">Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment</a></li>
</ul>

Large Cap

Contracts

ALPMF

ALPMY

SGMO

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Swiss pharmaceutical giant Roche Holding AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) reportedly has no plans for job cuts despite facing recent challenges in its drug development pipeline.
CEO Thomas Schinecker, in an interview with NZZ am Sonntag, reassured that worker numbers are constant to slightly increasing, reported Reuters.
He also emphasized healthy business and not having a growth problem either. Meanwhile, the report noted Schinecker&nbsp;saying that the company&#8217;s research and development budget remains stable without expansion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42597251/roche-prothena-partnered-mid-stage-parkinsons-trial-misses-primary-endpoint-but-cling-on-signs-of-clinical-benefits" rel="noreferrer noopener">Roche-Prothena Partnered Mid-Stage Parkinson&#8217;s Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits</a>
Schinecker also provided insights into Roche&#8217;s pipeline, estimating that the company&#8217;s anti-obesity drug could hit the market by 2029 or earlier, per the report.
Addressing the broader economic landscape, Schinecker acknowledged challenges in Europe and China, contrasting them with moderate growth in the U.S.
Price Action: RHHBY shares closed at $35.07 on Friday.

Equities

Media

Roche CEO Reassures No Job Cuts Despite Challenges: Report

On Thursday, Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released results from the Phase 2b PADOVA study of prasinezumab in early-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42568873/roches-phase-iib-study-of-prasinezumab-missed-primary-endpoint-but-suggests-possible-clinical-bene" rel="noreferrer noopener">stage Parkinson&#8217;s disease</a>.
Partner Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) conducted the 586-subject study investigating prasinezumab in early-stage Parkinson&#8217;s disease patients who had been treated for a minimum of 18 months while on stable symptomatic treatment.
Prasinezumab <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-12-19" rel="noreferrer noopener">showed</a> a potential clinical effect in the primary endpoint of time to confirmed motor progression with an HR=0.84 and p=0.0657, missing statistical significance.
The companies said the effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 and nominal p=0.0431.
Pre-specified supplementary covariate-adjusted analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81; nominal p=0.0334) and in the levodopa subgroup (HR=0.76; nominal p=0.0175).
Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study.
The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies will continue to explore the observed effects in both studies.
Roche will continue to evaluate the data and work together with health authorities to determine the next steps.
Full results from the PADOVA study will be presented at an upcoming medical meeting.
Price Action: PRTA stock is up 32.40% at $15.83 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>

PRTA

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

&#x2A;– PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints –– Prasinezumab continues to be well tolerated and no new safety signals were observed
&#x2A;– PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints –
– Prasinezumab continues to be well tolerated and no new safety signals were observed –
– Genentech is further evaluating the data and will work together with health authorities to determine next steps –

Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and <a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Crohn&#8217;s disease (CD)</a>.
In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.
BofA Securities raised the price target for Teva to $25 from $23 <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>, reflecting a strong Phase 2 data update for duvakitug in inflammatory bowel disorders (IBD).
Based on the strength of the data and the emerging product prole, the analyst forecasts nominal peak sales of ~$2 billion (booked by partner), with Teva booking half the profits.
Given the anticipated impact on profits by 2030, BofA factors in the long-term strength of Teva&#8217;s innovative portfolio by applying a valuation multiple of 9.25x to 2025 estimated EV/EBITDA.
Partnership milestone payments provide reliable cash flow, and the analyst sees potential for the stock to gain value as the company shifts toward growth-focused execution.
The TL1a drug class has emerged over the last two years, led by Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Prometheus&#8217; strong Phase 2 data, which was followed by similar data from Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) competitor asset.
BofA writes that TL1a was a class of drug that could offer a very good safety profile, on par with market-leading Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Entyvio, plus a high rate of efficacy across all major patient subgroups.
Data update from Teva in around 240 patients in Phase 2 showed 16%-27% placebo-adjusted MAYO remission scores in the UC population, with the high dose compared favorably to competitors.
TEVA Price Action: Teva Pharmaceutical stock is up 3.23% at $21.56 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease</a></li>
</ul>
Photo: Courtey Teva Pharmaceutical Industries

Analyst Color

Price Target

Analyst Ratings

TEVA

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

During 2000–2020, the U.K.'s National Health Service (NHS) faced significant trade-offs in prioritizing new drug treatments, as resources allocated to these medications often came at the expense of broader population health gains.
Lancet research revealed that while newly approved drugs directly benefit certain patients, the overall impact on population health was negative due to the high costs and resulting resource reallocation.
A retrospective analysis reviewed technology appraisals conducted by the National Institute for Health and Care Excellence (NICE) on 332 drugs.
Of these, 276 (83%) received positive recommendations, and most were appraised within five years of regulatory approval.
The study ultimately included 183 drugs after excluding ineligible cases. While these drugs generated an estimated 3.75 million quality-adjusted life years (QALYs) across 19.82 million patients, their cost to the NHS—totaling $94.93 billion (75.1 billion pounds)—led to an estimated net loss of 1.25 million QALYs.
For example, oncology drugs demonstrated a median cost-effectiveness ratio (ICER) of 30,000 pounds per QALY gained, significantly higher than the 6,478 pounds for anti-infective drugs.
Additionally, the ICER for new drug recommendations rose by 32% from 2000 to 2020, reflecting increased financial pressures on the NHS.
Despite potential long-term benefits from price reductions after patent expiration, these effects were limited. Only 19% of the studied drugs had generic or biosimilar alternatives by 2020.
For new drugs to contribute positively to population health, their initial costs would have required a median reduction of 42%.
The ongoing debate around NICE's cost-effectiveness threshold remains central to policy discussions.
A 2024 agreement retained the current threshold until 2029, but experts argue for alignment with the Department of Health and Social Care's estimate of health-opportunity costs.
Such an adjustment could ensure the NHS achieves better value for its investments in new drugs without compromising care quality in other areas.
Balancing innovation with equitable health outcomes requires nuanced policy solutions. The study <a target="_blank" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02352-3/fulltext" rel="noreferrer noopener">suggests</a> a lower cost-effectiveness threshold, closer to 15,000 pounds per QALY, could better align spending with health gains.
However, opposition from the pharmaceutical industry underscores the challenges of reforming pricing policies while fostering innovation.
This approach highlights how benefiting one group of patients may require deprioritizing others as existing NHS services and treatments are displaced to fund new drugs.
For instance, in 2010, NICE approved Roche Holding AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Herceptin (trastuzumab) for metastatic gastric cancer, deeming an ICER of 43,206 pounds per QALY gained as cost-effective.
Framing this as 2.88 QALYs forgone for every QALY gained clarifies the value placed on patients receiving the treatment versus those who might lose out on care.
At a population level, using trastuzumab in this context resulted in an estimated 4,000 QALYs lost between 2010 and 2020.
However, adopting this perspective could pose challenges for policymakers due to the established 20,000–30,000 pounds per QALY threshold.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42469841/cf-industries-50m-quarterly-ebitda-potential-from-carbon-capture-credits-starting-q4-2025-analyst-says" target="_blank" rel="noreferrer noopener">CF Industries Carbon Capture Credits EBITDA Potential Could Be As High As $50 Million: Analyst</a></li>
</ul>
Photo by Martin Gregor via Shutterstock

Government

Eurozone

EWUS

FLGB

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis

– Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less frequent dosing –
– First presentation of Lunsumio given subcutaneously showed non-inferiority to intravenous treatment with a consistent safety profile, potentially providing an additional outpatient option with a shorter administration time –
– Positive results for Genentech's two bispecifics antibodies validate the company's efforts to provide multiple treatment options that suit the diverse needs of lymphoma patients and healthcare providers –

Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio

<ul>
<li>– Exploratory long-term follow-up analysis of the Phase III POLARIX study indicated a positive trend in overall survival in favor of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL) –</li>
<li>– Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems –</li>
<li>– These encouraging five-year results continue to highlight the potential of this Polivy combination to improve outcomes in first-line DLBCL, an area that previously had little advancement in nearly two decades –</li>
</ul>

Reported Sunday, Roche's Genentech Showcases Polivy's Transformative Impact On Frontline DLBCL Treatment: Five-Year POLARIX Trial Results Presented At ASH 2024

<ul>
<li>Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival&nbsp;</li>
<li>This regimen could provide an off-the-shelf, fixed-duration treatment option for patients to start soon after diagnosis, which is important for those who are at high-risk of disease progression&nbsp;</li>
<li>Improving survival outcomes is needed for people with an aggressive disease like relapsed or refractory DLBCL, especially those who aren't eligible for transplant&nbsp;</li>
<li>The FDA is expected to make a decision on approval by July 20, 2025.</li>
</ul>

FDA Accepts Genentech's sBLA For Columvi Combination Therapy For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Outlook Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42210551/outlook-therapeutics-announces-preliminary-topline-results-of-norse-eight-clinical-trial" rel="noreferrer noopener">wet AMD patients</a>.
In the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified noninferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA.
The pre-specified noninferiority endpoint was measured by mean change in best corrected visual acuity (BCVA) from baseline to week 8.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
The difference in the means between the ONS-5010 and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) in the NORSE EIGHT trial was -2.257 BCVA letters, while the lower bound of the pre-specified noninferiority margin in the SPA was -3.5; the hypothesis of noninferiority was not met (p&gt;0.025).&nbsp;
In the intent-to-treat (ITT) primary dataset, NORSE EIGHT demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010 arm and +6.3 letter improvement in BCVA in the ranibizumab arm.
However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010.
Data analysis is ongoing as month 3 data from NORSE EIGHT are being collected. The data is expected to be available in January 2025.
Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, Outlook Therapeutics plans to resubmit the U.S. marketing application for ONS-5010 in the first quarter of calendar 2025.
ONS-5010/Lytenava (bevacizumab gamma) has already been granted Marketing Authorization in the European Union and the U.K.
Outlook Therapeutics intends to continue efforts to launch in Europe in 2025, either directly or with a licensing partner.
If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/Lytenava (bevacizumab-vikg) directly in the U.S. It is also assessing partnering options for Lytenava (bevacizumab gamma) in Europe and other regions <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40706252/outlook-therapeutics-announces-completion-of-enrollment-in-norse-eight-clinical-trial" rel="noreferrer noopener">outside of the U.S.</a>
Price Action: OTLK stock is down 80% at $0.97 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42213279/whats-going-on-with-us-listed-chinese-stocks-alibaba-jd-nio-li-xpeng-on-wednesday-2" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With US Listed Chinese Stocks Alibaba, JD, Nio, Li, XPeng On Wednesday?</a></li>
</ul>
Photo by Amanda Dalbjörn on Unsplash.

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

On Tuesday, Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) for an equity value of approximately&nbsp;$1.5 billion&nbsp;on a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42180905/poseida-therapeutics-inc-announces-agreement-to-be-acquired-by-roche-holdings-inc" rel="noreferrer noopener">fully diluted basis</a>.
The deal consideration includes $9.00&nbsp;per share in cash plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of&nbsp;$4.00&nbsp;per share in cash upon achievement of specific milestones.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41505575/roches-q3-sales-surge-led-by-ocrevus-vabysmo-urges-regulators-to-block-novo-holdings-16-5b-catale" rel="noreferrer noopener">Roche&#8217;s Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings&#8217; $16.5B Catalent Acquisition</a>
The proposed acquisition will establish a new core capability for&nbsp;Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.
It will include CAR-T programs for solid tumors and autoimmune diseases, Poseida&#8217;s genetic engineering platform, and related preclinical medicines.
The acquisition <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-11-26b" rel="noreferrer noopener">supports</a> Roche&#8217;s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies.
In its third-quarter earnings release, Poseida said it has three programs under Roche collaboration announced in August 2022, including P-BCMA-ALLO1, an allogeneic CAR-T therapy in Phase 1/1b&nbsp;development for multiple myeloma, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T candidate in Phase 1 development for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41823822/poseida-therapeutics-provides-updates-and-financial-results-for-the-third-quarter-of-2024" rel="noreferrer noopener">B-cell malignancies</a>.&nbsp;
In October, Poseida Therapeutics nominated a new development candidate under its collaboration with Roche. The nomination triggered a&nbsp;$15 million&nbsp;milestone payment from Roche to Poseida.
The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41378041/poseida-therapeutics-announces-nomination-of-new-car-t-development-candidate-under-collaboration-w" rel="noreferrer noopener">hematologic malignancies</a>.
The transaction is expected to close in the first quarter of 2025.
Concurrently, Roche <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-11-26" rel="noreferrer noopener">revealed</a> an update on the Phase 3 SKYSCRAPER-01 study of tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).&nbsp;
The 534-patient study did not reach the primary endpoint of overall survival at the final analysis.
The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Roche regularly evaluates its research programs to see if changes are needed to support ongoing studies. The same approach will be applied to this program, with more data from Phase 3 trials in various settings or tumor types expected next year.
Price Action: PSTX stock is up 227.3% at $9.36 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42184005/rivian-to-expand-us-ev-production-with-66-billion-doe-loan" target="_blank" rel="noreferrer noopener">Rivian Rides High: $6.6 Billion DOE Loan Commitment Fuels EV Expansion</a></li>
</ul>
Photo via Shutterstock.

PSTX

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

SKYSCRAPER-01 is a global Phase III, randomized, double-blinded study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.

Roche's Genentech Provides Update On SKYSCRAPER-01 Phase III Study In PD-L1-High NSCLC Patients

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion
Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals

Poseida Therapeutics To Be Acquired bB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash

<ul>
<li>The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated,&nbsp;unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.</li>
<li>There are currently very few options for&nbsp;BTC patients as most cases are at an advanced stage at the time of diagnosis.</li>
<li>This approval represents a new indication for&nbsp;Roche's existing PATHWAY HER2 (4B5) test and expands its clinical utility by broadening the scope of patients who are eligible for HER2-targeted therapies.</li>
</ul>

Roche Wins FDA Approval For The First Diagnostic To Identify Biliary Tract Cancer Patients For HER2-Targeted Therapy With ZIIHERA

<ul>
<li>The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.</li>
<li>The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE. &nbsp;</li>
<li>This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.</li>
</ul>

Roche Secures CE Mark For VENTANA FOLR1 RxDx Assay, The First IHC Diagnostic For Identifying Epithelial Ovarian Cancer Patients Eligible For ELAHERE

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. 
According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. 
This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.
Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. 
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. 
Similarly, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.
Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. 
Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.
On the downside, Wegovy maker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.
Similarly, Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. 
Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.
&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why">ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</a></li>
</ul>
Image Via Shutterstock

ABBV

ALNY

GILD

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Recursion Pharmaceuticals: Betting Big On AI

Roche (RHHBY) announced that it has received 510(k) clearance from the FDA for its highly-sensitive in-situ hybridisation test, the Ventana Kappa a...

Roche receives FDA clearance for B-cell lymphoma diagnostic test

Arcus: Excellent Pipeline And Collaborations, Cash Runway

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a price t...

Goldman Sachs Remains a Sell on Roche Holding AG (RHHVF)

In a report released today, Richard Vosser from J.P. Morgan maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a price ta...

J.P. Morgan Sticks to Its Sell Rating for Roche Holding AG (RHHVF)

Several large drugmakers will ask the Trump administration to pause Medicare drug price negotiations, even as Biden-appointed officials prepare a n...

Drugmakers to push Trump to pause price negotiations, Bloomberg reports

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)

Outlook falls 10% on ONS-5010 update, warrant inducements

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

Chinese biotech dominance in R&D is on the rise

ABCL

AKESF

AZNCF

BAYRY

BAYZF

CGON

HNSPF

ILMN

ITCI

NVDA

NVSEF

RCUS

REGN

RLAY

RXRX

SMMT

SNYNF

TCHBF

TGTX

Press Releases

FDA Accepts Supplemental Biologics License Application for Genentech's Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Five-Year Results Confirm Genentech's Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma

Comments

Roche Holding

空売り

Roche Holding (OTC:RHHBY) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル